Girish N Nadkarni1, Kinsuk Chauhan2, Veena Rao3, Joachim H Ix4, Michael G Shlipak5, Chirag R Parikh6, Steven G Coca7. 1. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: girish.nadkarni@mountsinai.org. 2. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 3. Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT. 4. Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA; Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA; Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA. 5. Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA; Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, San Francisco, CA. 6. Program of Applied Translational Research, Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, New Haven, CT. 7. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: steven.coca@mssm.edu.
Abstract
RATIONALE & OBJECTIVE: Random assignment to intensive blood pressure (BP) lowering (systolic BP<120mmHg) compared to a less intensive BP target (systolic BP<140mmHg) in the Action to Control Cardiovascular Risk in Diabetes BP (ACCORD-BP) trial resulted in a more rapid decline in estimated glomerular filtration rate (eGFR). Whether this reflects hemodynamic effects or intrinsic kidney damage is unknown. STUDY DESIGN: Longitudinal analysis of a subgroup of clinical trial participants. SETTINGS & PARTICIPANTS: A subgroup of 529 participants in ACCORD-BP. EXPOSURES: Urine biomarkers of tubular injury (kidney injury molecule 1, interleukin 18 [IL-18]), repair (human cartilage glycoprotein 39 [YKL-40]), and inflammation (monocyte chemoattractant protein 1) at baseline and year 2. OUTCOMES: Changes in eGFR from baseline to 2 years. ANALYTICAL APPROACH: We compared changes in biomarker levels and eGFRs across participants treated to an intensive versus less intensive BP goal using analysis of covariance. RESULTS: Of 529 participants, 260 had been randomly assigned to the intensive and 269 to the standard BP arm. Mean age was 62±6.5 years and eGFR was 90mL/min/1.73m2. Baseline clinical characteristics, eGFRs, urinary albumin-creatinine ratios (ACRs), and urinary biomarker levels were similar across BP treatment groups. Compared to less intensive BP treatment, eGFR was 9.2mL/min/1.73m2 lower in the intensive BP treatment group at year 2. Despite the eGFR reduction, within this treatment group, ACR was 30% lower and 4 urinary biomarker levels were unchanged or lower at year 2. Also within this group, participants with the largest declines in eGFRs had greater reductions in urinary IL-18 and YKL-40 levels. In a subgroup analysis of participants developing incident chronic kidney disease (sustained 30% decline and eGFR<60mL/min/1.73m2; n=77), neither ACR nor 4 biomarker levels increased in the intensive treatment group, whereas the level of 1 biomarker, IL-18, increased in the less intensive treatment group. LIMITATIONS: Few participants with advanced baseline chronic kidney disease. Comparisons across treatment groups do not represent comparisons of treatment arms created solely through randomization. CONCLUSIONS: Among a subset of ACCORD-BP trial participants, intensive BP control was associated with reductions in eGFRs, but not with an increase in injury marker levels. These findings support that eGFR decline observed with intensive BP goals in ACCORD participants may predominantly reflect hemodynamic alterations.
RCT Entities:
RATIONALE & OBJECTIVE: Random assignment to intensive blood pressure (BP) lowering (systolic BP<120mmHg) compared to a less intensive BP target (systolic BP<140mmHg) in the Action to Control Cardiovascular Risk in Diabetes BP (ACCORD-BP) trial resulted in a more rapid decline in estimated glomerular filtration rate (eGFR). Whether this reflects hemodynamic effects or intrinsic kidney damage is unknown. STUDY DESIGN: Longitudinal analysis of a subgroup of clinical trial participants. SETTINGS & PARTICIPANTS: A subgroup of 529 participants in ACCORD-BP. EXPOSURES: Urine biomarkers of tubular injury (kidney injury molecule 1, interleukin 18 [IL-18]), repair (humancartilage glycoprotein 39 [YKL-40]), and inflammation (monocyte chemoattractant protein 1) at baseline and year 2. OUTCOMES: Changes in eGFR from baseline to 2 years. ANALYTICAL APPROACH: We compared changes in biomarker levels and eGFRs across participants treated to an intensive versus less intensive BP goal using analysis of covariance. RESULTS: Of 529 participants, 260 had been randomly assigned to the intensive and 269 to the standard BP arm. Mean age was 62±6.5 years and eGFR was 90mL/min/1.73m2. Baseline clinical characteristics, eGFRs, urinary albumin-creatinine ratios (ACRs), and urinary biomarker levels were similar across BP treatment groups. Compared to less intensive BP treatment, eGFR was 9.2mL/min/1.73m2 lower in the intensive BP treatment group at year 2. Despite the eGFR reduction, within this treatment group, ACR was 30% lower and 4 urinary biomarker levels were unchanged or lower at year 2. Also within this group, participants with the largest declines in eGFRs had greater reductions in urinary IL-18 and YKL-40 levels. In a subgroup analysis of participants developing incident chronic kidney disease (sustained 30% decline and eGFR<60mL/min/1.73m2; n=77), neither ACR nor 4 biomarker levels increased in the intensive treatment group, whereas the level of 1 biomarker, IL-18, increased in the less intensive treatment group. LIMITATIONS: Few participants with advanced baseline chronic kidney disease. Comparisons across treatment groups do not represent comparisons of treatment arms created solely through randomization. CONCLUSIONS: Among a subset of ACCORD-BP trial participants, intensive BP control was associated with reductions in eGFRs, but not with an increase in injury marker levels. These findings support that eGFR decline observed with intensive BP goals in ACCORD participants may predominantly reflect hemodynamic alterations.
Authors: Sushrut S Waikar; Venkata Sabbisetti; Johan Ärnlöv; Axel C Carlsson; Josef Coresh; Harold I Feldman; Meredith C Foster; Gudeta D Fufaa; Johanna Helmersson-Karlqvist; Chi-Yuan Hsu; Paul L Kimmel; Anders Larsson; Yumin Liu; Lars Lind; Kathleen D Liu; Theodore E Mifflin; Robert G Nelson; Ulf Risérus; Ramachandran S Vasan; Dawei Xie; Xiaoming Zhang; Joseph V Bonventre Journal: Nephrol Dial Transplant Date: 2016-06-07 Impact factor: 5.992
Authors: Michael G Shlipak; Rebecca Scherzer; Alison Abraham; Phyllis C Tien; Carl Grunfeld; Carmen A Peralta; Prasad Devarajan; Michael Bennett; Anthony W Butch; Kathryn Anastos; Mardge H Cohen; Marek Nowicki; Anjali Sharma; Mary A Young; Mark J Sarnak; Chirag R Parikh Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Meyeon Park; Chi-Yuan Hsu; Alan S Go; Harold I Feldman; Dawei Xie; Xiaoming Zhang; Theodore Mifflin; Sushrut S Waikar; Venkata S Sabbisetti; Joseph V Bonventre; Josef Coresh; Robert G Nelson; Paul L Kimmel; John W Kusek; Mahboob Rahman; Jeffrey R Schelling; Ramachandran S Vasan; Kathleen D Liu Journal: Clin J Am Soc Nephrol Date: 2017-03-02 Impact factor: 8.237
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Rita Magriço; Miguel Bigotte Vieira; Catarina Viegas Dias; Lia Leitão; João Sérgio Neves Journal: Clin J Am Soc Nephrol Date: 2017-11-03 Impact factor: 8.237
Authors: Kinsuk Chauhan; Girish N Nadkarni; Neha Debnath; Lili Chan; Aparna Saha; Amit X Garg; Chirag R Parikh; Steven G Coca Journal: Clin J Am Soc Nephrol Date: 2019-08-13 Impact factor: 8.237
Authors: Edouard L Fu; Marco Trevisan; Catherine M Clase; Marie Evans; Bengt Lindholm; Joris I Rotmans; Merel van Diepen; Friedo W Dekker; Juan-Jesus Carrero Journal: Clin J Am Soc Nephrol Date: 2019-08-08 Impact factor: 8.237
Authors: Jonathan G Amatruda; Ronit Katz; Carmen A Peralta; Michelle M Estrella; Harini Sarathy; Linda F Fried; Anne B Newman; Chirag R Parikh; Joachim H Ix; Mark J Sarnak; Michael G Shlipak Journal: J Am Geriatr Soc Date: 2020-12-10 Impact factor: 5.562
Authors: Kuldeep Dhama; Shyma K Latheef; Maryam Dadar; Hari Abdul Samad; Ashok Munjal; Rekha Khandia; Kumaragurubaran Karthik; Ruchi Tiwari; Mohd Iqbal Yatoo; Prakash Bhatt; Sandip Chakraborty; Karam Pal Singh; Hafiz M N Iqbal; Wanpen Chaicumpa; Sunil Kumar Joshi Journal: Front Mol Biosci Date: 2019-10-18
Authors: Rakesh Malhotra; Timothy Craven; Walter T Ambrosius; Anthony A Killeen; William E Haley; Alfred K Cheung; Michel Chonchol; Mark Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix Journal: Am J Kidney Dis Date: 2018-10-02 Impact factor: 8.860
Authors: Alex R Chang; Holly Kramer; Guo Wei; Robert Boucher; Morgan E Grams; Dan Berlowitz; Udayan Bhatt; Debbie L Cohen; Paul Drawz; Henry Punzi; Barry I Freedman; William Haley; Amret Hawfield; Edward Horwitz; Christopher McLouth; Don Morisky; Vasilios Papademetriou; Michael V Rocco; Barry Wall; Daniel E Weiner; Athena Zias; Srinivasan Beddhu Journal: Clin J Am Soc Nephrol Date: 2020-07-15 Impact factor: 8.237